|
[Related PubMed/MEDLINE]
Total Number of Papers: 24
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: PDE5 |
| Long Form |
: phosphodiesterase type 5 inhibitors |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2021 |
Exploring the potentials of some compounds from Garcinia kola seeds towards identification of novel PDE-5 inhibitors in erectile dysfunction therapy. |
ED |
| 2 |
2018 |
Simulation Strategies for Characterizing Phosphodiesterase-5 Inhibitors in Botanical Dietary Supplements. |
BDSs, DFT, DS, PC, SERS, SPR, TLC |
| 3 |
2016 |
Development and evaluation of an immunochromatographic strip for rapid screening of sildenafil-type compounds as illegal additives in functional foods. |
ELISA, IC |
| 4 |
2016 |
Erectile Dysfunction Medication Use in Veterans Eligible for Medicare Part D. |
ED, VA |
| 5 |
2014 |
Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats. |
DM-I |
| 6 |
2014 |
Icariin combined with breviscapine improves the erectile function of spontaneously hypertensive rats. |
eNOS, nNOS, NO, SHR, WKY |
| 7 |
2013 |
Inhibition of phosphodiesterase 4 enhances clitoral and vaginal blood flow responses to dorsal clitoral nerve stimulation or PGE1 in anesthetized female rats. |
cAMP, DCN, L-NNA, MAP, PDE4, PGE1, TPU |
| 8 |
2013 |
Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. |
ED, MSD, PE |
| 9 |
2013 |
[Evaluation of the management of erectile and ejaculatory dysfunction in a series of 90 patients with spinal cord injuries]. |
CMI |
| 10 |
2012 |
A survey on illegal and counterfeit medicines for the treatment of erectile dysfunctions in Italy. |
--- |
| 11 |
2012 |
Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era--an ecological study. |
CCI, DSH, ED, IIEF-EF |
| 12 |
2012 |
Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. |
ED |
| 13 |
2012 |
Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? |
BNSRP, CCI, ED, EF, IIEF |
| 14 |
2012 |
Exploring the association between erectile rigidity and treatment adherence with sildenafil. |
ED, EF, EHS, EOT, IIEF |
| 15 |
2011 |
Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. |
ETB, HIF-1alpha, LUT, PDE5i, SHR, WKY |
| 16 |
2011 |
Phosphodiesterase type 5 inhibitor abuse: a critical review. |
FDA, VIPPS |
| 17 |
2009 |
Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? |
--- |
| 18 |
2009 |
Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. |
ISSM, RP |
| 19 |
2009 |
Tadalafil for the treatment of pulmonary arterial hypertension. |
PAH |
| 20 |
2009 |
The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. |
--- |
| 21 |
2007 |
[Sexual activity and cardiovascular risk]. |
MI, PTCA |
| 22 |
2006 |
PDE5 inhibitors: are there differences? |
ED |
| 23 |
2005 |
Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. |
--- |
| 24 |
2002 |
Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. |
ED |
|
A Search Service for Abbreviation / Long Form
